Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 22INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Endocrine 2Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 927Neoplasms 612Breast Neoplasms 611Colorectal Neoplasms 458Neoplasm Metastasis 398Ovarian Neoplasms 333Prostatic Neoplasms 316Melanoma 316Lung Neoplasms 294Multiple Myeloma 293Recurrence 281Squamous Cell Carcinoma of Head and Neck 248Stomach Neoplasms 232Pancreatic Neoplasms 231Leukemia, Myeloid, Acute 224Triple Negative Breast Neoplasms 193Endometrial Neoplasms 190Carcinoma, Renal Cell 183Lymphoma, Non-Hodgkin 178Carcinoma, Hepatocellular 178Small Cell Lung Carcinoma 166Leukemia, Lymphocytic, Chronic, B-Cell 158Advanced Solid Tumors 158Lymphoma, Follicular 150Lymphoma, Large B-Cell, Diffuse 141Urinary Bladder Neoplasms 140Lymphoma 138Advanced Solid Tumor 137Uterine Cervical Neoplasms 136Head and Neck Neoplasms 134

Interventions

dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Thyroid Carcinoma, Anaplastic × 1 year × Clear all
NCT07181720 2025-10-02

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Chongqing Precision Biotech Co., Ltd

Phase 1 Recruiting
90 enrolled
EndocrineGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thymoma, Thyroid Carcinoma, Anaplastic

NCT04418167 2025-09-03

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

JS InnoPharm, LLC

Phase 1 Suspended
71 enrolled
DermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡